In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Biogen (BIIB – Research Report), with a price ...

Bernstein started coverage of Eli Lilly (NYSE:LLY), Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) with outperform ratings. The investment firm said its bullish ratings on Gilead and Amgen were ...

Jefferies analyst Michael Yee maintained a Buy rating on Biogen (BIIB – Research Report) today and set a price target of $250.00. The ...

"The global regenerative medicine markets comprises of many key market players competing for markets shares like Novartis AG ...

The prevailing sentiment among analysts is an Neutral trajectory for Amgen, with an average 1-year price target of $347.8, implying a potential 287.13% upside. Gilead Sciences ranks in the middle ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings estimates and raised its guidance, boosted by demand for its HIV and ...

November 06, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the ...

Bernstein started coverage of Eli Lilly (NYSE:LLY), Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) with outperform ratings. The investment firm said its bullish ratings on Gilead and Amgen ...

Gilead Sciences (NASDAQ:GILD) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Gilead ...